Current Atherosclerosis Reports

, Volume 1, Issue 1, pp 6–8 | Cite as

Reducing atherothrombotic events in high-risk patients: Recent data on therapy with statins and fatty acids

  • Christie M. Ballantyne
Clinical Trials Review


Traditional treatment of atherosclerotic coronary heart disease by cardiovascular specialists, which has focused on “critical” stenoses, may be less effective in reducing morbidity and mortality than therapies that stabilize plaques and reduce thrombosis and sudden death. Recent data from clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy and modification of dietary fat composition demonstrate that both these approaches can reduce clinical events. Although revascularization therapy is effective in reducing angina caused by high-grade stenotic lesions, this therapy is incomplete because the more-numerous “smaller” plaques that typically cause clinical events remain untreated. Two recent trials suggest that statin therapy may have benefits on stabilizing plaques in high-risk patients within a year. Additional benefit may also be provided by increasing dietary consumption of monounsaturated or omega-3 polyunsaturated fatty acids. Both statin therapy and diets high in monounsaturated or omega-3 fatty acids appear to improve morbidity and mortality by modifying the underlying atherothrombotic disease process.


Atorvastatin Statin Therapy Fluvastatin Angiographic Restenosis Major Adverse Coronary Event 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Serruys PW, Foley DP, Jackson G, et al., on behalf of the FLARE study group: A randomized placebo-controlled trial of fluvastatin for preventiton of restenosis after successful coronary balloon angioplasty: final results of the Fluvastatin Angiographic Restenosis (FLARE) Trial. Eur Heart J 1999, 20:58–69.PubMedCrossRefGoogle Scholar
  2. 2.
    Weintraub WS, Boccuzzi SJ, Klein JL, et al., for the Lovastatin Restenosis Trial Study Group: Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994, 331:1331–1337.PubMedCrossRefGoogle Scholar
  3. 3.
    Bertrand ME, McFadden EP, Fruchart JC, et al., for the PREDICT Trial Investigators: Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1997, 30:863–869.PubMedCrossRefGoogle Scholar
  4. 4.
    McCormick LS, Black DM, Waters D, et al., for the AVERT Investigators: Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with atorvastatin versus revascularization treatments (AVERT). Am J Cardiol 1997, 80:1130–1133.PubMedCrossRefGoogle Scholar
  5. 5.
    de Lorgeril M, Renaud S, Mamelle N, et al.: Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994, 343:1454–1459.PubMedCrossRefGoogle Scholar
  6. 6.
    de Lorgeril M, Salen P, Martin J-L, et al.: Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease: insights into the cardioprotective effect of certain nutriments. J Am Coll Cardiol 1996, 28:1103–1108.PubMedCrossRefGoogle Scholar
  7. 7.
    de Lorgeril M, Salen P, Martin J-L, et al.: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999, 99:779–785.PubMedGoogle Scholar
  8. 8.
    Leaf A: Dietary prevention of coronary heart disease: the Lyon Diet Heart Study [editorial]. Circulation 1999, 99:733–735.PubMedGoogle Scholar

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • Christie M. Ballantyne
    • 1
  1. 1.Department of MedicineBaylor College of MedicineHouston

Personalised recommendations